NASDAQ: GLYCGlycomimetics Inc Stock Ownership - Who owns Glycomimetics?
Insider buying vs selling
Have Glycomimetics Inc insiders been buying or selling?
Buy
Sell
| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Daniel M. Junius | Director | 2024-03-29 | 5,209 | $3.00 | $15.63kBuy |
| Mark Alan Goldberg | Director | 2024-03-29 | 4,584 | $3.00 | $13.75kBuy |
| Rachel K. King | Director | 2024-03-29 | 3,334 | $3.00 | $10.00kBuy |
| Mark Alan Goldberg | Director | 2023-12-29 | 5,827 | $2.36 | $13.75kBuy |
| Rachel K. King | Director | 2023-12-29 | 4,238 | $2.36 | $10.00kBuy |
| Patricia S. Andrews | Director | 2023-12-29 | 5,191 | $2.36 | $12.25kBuy |
| Patricia S. Andrews | Director | 2023-09-30 | 8,167 | $1.50 | $12.25kBuy |
| Rachel K. King | Director | 2023-09-30 | 6,667 | $1.50 | $10.00kBuy |
| Mark Alan Goldberg | Director | 2023-09-30 | 9,167 | $1.50 | $13.75kBuy |
| Edwin Rock | Chief Medical Officer | 2023-09-22 | 30,403 | $1.38 | $41.96kBuy |
GLYC insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership
Be the first to know when GLYC insiders and whales buy or sell their stock.
GLYC Shareholders
What type of owners hold Glycomimetics Inc stock?
Institutional
Insider
Retail
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Scott D. Sandell | 21.81% | 14,056,571 | $32.05M | Insider |
| M. James Barrett | 20.45% | 13,182,418 | $30.06M | Insider |
| Peter J. Barris | 20.45% | 13,182,418 | $30.06M | Insider |
| Bvf Inc | 14.81% | 9,544,262 | $21.76M | Institution |
| Invus Public Equities LP | 13.33% | 8,589,064 | $19.58M | Insider |
| Artal Group Sa | 13.33% | 8,589,064 | $19.58M | Institution |
| New Enterprise Associates 10 L P | 7.75% | 4,995,664 | $11.39M | Insider |
| Nea Management Company LLC | 7.39% | 4,764,440 | $10.86M | Institution |
| New Enterprise Associates 13 LP | 6.35% | 4,093,377 | $9.33M | Insider |
| Octagon Capital Advisors LP | 4.65% | 3,000,000 | $6.84M | Institution |
GLYC vs Biotech Stocks
Glycomimetics Stock Ownership FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.